Wall Street analyst estimates for TuHURA Biosciences, Inc. (HURA): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
TuHURA Biosciences, Inc. is an immuno-oncology firm that has reached the critical Phase 3 registration stage of clinical development. The company is dedicated to pioneering innovative technologies designed to effectively combat the mechanisms by which cancers develop resistance to existing immunotherapy treatments. Its operations are based in Tampa, Florida.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-13 | $-0.14 | ||
| 2026-08-13 | $-0.14 | $-0.15 | +8.7% |
| 2026-05-15 | $-0.13 | $-0.12 | -8.3% |
| 2026-03-31 | $-0.12 | $-0.12 | -1.4% |
| 2025-11-14 | $-0.14 | $-0.15 | +6.7% |
| 2025-08-14 | $-0.21 | $-0.14 | -50.0% |
| 2025-05-15 | $-0.15 | $-0.13 | -15.4% |
| 2025-02-26 | $-8.39 | $-0.09 | -9222.2% |
Valuation Ratios
| Price / Book | 7.09 |
| EV / EBITDA | -4.38 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $16683 | $24528 | $16348 | $10000 | $32000 | $60000 | $60000 | $55000 | 0 | 0 |
| Gross Profit | -$16683 | -$24528 | -$16348 | -$10000 | -$32000 | -$60000 | -$60000 | -$55000 | 0 | 0 |
| Research & Development | $5.0M | $7.1M | $3.7M | $3.6M | $11.8M | $15.2M | $9.3M | $2.7M | $13.3M | $20.5M |
| Selling, General & Admin | $3.3M | $4.0M | $4.7M | $4.5M | $9.7M | $7.4M | $5.4M | $5.7M | $3.9M | $7.6M |
| Operating Expenses | $8.3M | $11.2M | $8.4M | $8.1M | $21.5M | $22.6M | $14.7M | $8.4M | $17.6M | $31.8M |
| Operating Income | -$8.3M | -$11.2M | -$8.4M | -$8.1M | -$21.6M | -$22.7M | -$14.8M | -$8.5M | -$17.6M | -$31.8M |
| EBITDA | -$8.1M | -$11.1M | -$8.0M | -$9.1M | -$38.1M | -$22.0M | -$14.6M | -$8.3M | -$17.4M | -$29.4M |
| Interest Expense | 0 | 0 | 0 | 0 | $120000 | $629286 | 0 | $18688 | $4.1M | $625283 |
| Pre-tax Income | -$8.1M | -$11.1M | -$8.0M | -$9.1M | -$38.3M | -$22.7M | -$14.6M | -$8.3M | -$21.7M | -$30.1M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$8.1M | -$11.1M | -$8.0M | -$9.1M | -$38.3M | -$22.7M | -$14.6M | -$8.3M | -$21.7M | -$30.1M |
| EPS | $-12950.00 | $-9491.47 | $-5524.99 | $-1532.00 | $-2805.84 | $-903.03 | $-324.48 | $-11.29 | $-1.21 | $-0.63 |
| EPS (Diluted) | $-12950.00 | $-9491.47 | $-5524.99 | $-1532.00 | $-2805.84 | $-903.03 | $-324.48 | $-11.29 | $-1.21 | $-0.63 |
| Shares Outstanding (Diluted) | $688 | $1192 | $1471 | $5968 | $14791 | $27829 | $46285 | $752914 | $18.7M | $47.9M |
Price
| Price | $2.03 |
| Market Cap | $129M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABOS · AGEN · CGTX · INO · IRD · MCRB · SEER
Explore sector: Healthcare · Biotechnology
More sections of HURA: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks